TRAEs
| Camrelizumab plus apatinib (n=28) | ||
| Any grade | Grade≥3 | |
| TRAEs | ||
| Any | 28 (100) | 26 (92.9) |
| Serious | 4 (14.3) | 3 (10.7) |
| Any grade TRAEs occurring in at least 15% of patients | ||
| Clinical TRAEs | ||
| White blood cell count decreased | 16 (57.1) | 1 (3.6) |
| Aspartate aminotransferase increased | 16 (57.1) | 2 (7.1) |
| Platelet count decreased | 16 (57.1) | 4 (14.3) |
| Bilirubin conjugated increased | 13 (46.4) | 2 (7.1) |
| Blood bilirubin increased | 12 (42.9) | 1 (3.6) |
| Alanine aminotransferase increased | 11 (39.3) | 2 (7.1) |
| Biological TRAEs | ||
| Hypertension | 20 (71.4) | 9 (32.1) |
| Neutrophil count decreased | 15 (53.6) | 5 (17.9) |
| Proteinuria | 14 (50.0) | 1 (3.6) |
| Hand–foot syndrome | 10 (35.7) | 3 (10.7) |
| Hypothyroidism | 7 (25.0) | 0 |
| Diarrhea | 6 (21.4) | 2 (7.1) |
| RCCEP | 6 (21.4) | 0 |
| Decreased appetite | 6 (21.4) | 0 |
| Fatigue | 5 (17.9) | 1 (3.6) |
| Anemia | 5 (17.9) | 2 (7.1) |
Data are shown in n (%).
TRAE, treatment-related adverse event; RCCEP, reactive cutaneous capillary endothelial proliferation.